The U.S. Food and Drug Administration approved Oncopeptides AB’s Pepaxto (melphalan flufenamide) in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
Humanigen Inc. and EVERSANA announced that they are partnering to make lenzilumab available to hospitalized and hypoxic Covid-19 patients in the event that an Emergency Use Authorization is issued from the U.S. Food and Drug Administration and subsequent BLA.
Soliton Inc. selected Greater Than One Group as the medical device company’s integrated marketing agency.
Shares of Cambridge, Mass.-based Biogen were down after Mylan announced the launch of the first generic version of the top-selling multiple sclerosis drug Tecfidera.
Eli Lilly is moving quickly to get the newly approved precision oncology treatment Retevmo for certain lung and thyroid cancers into the hands of patients.
Shares of New York-based Stemline Therapeutics skyrocketed more than 153 percent in trading after Italy’s Menarini Group announced a $667 million acquisition of the oncology-focused company.
Deaf-owned software company Wavio announced a strategic partnership with AREA 23, an FCB Health Network Company, which includes a major investment deal for the development and product launch of “See Sound.” Created by AREA 23 and Wavio, the revolutionary home device is scheduled to launch during 2020. The partnership provides the FCB Health Network with company equity in Wavio and revenue share on product sales.
Over the next six years, 10 drugs that are in the pre-registration phase and expected to launch during 2020 are projected to reach blockbuster status.
Neurelis Inc. announced the commercial availability of Valtoco (diazepam nasal spray) for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in adult and pediatric patients 6 years of age and older.
Eli Lilly priced the company’s acute migraine treatment Reyvow at $640 for a pack of eight pills.